Teva fined EUR462.6 million for abusing patent system to defend MS drug
Teva Pharmaceuticals must pay a fine of 462.6 million euros for harming competition by hindering challengers to its blockbuster multiple sclerosis treatment. The European Commission sanctioned the company, saying it “artificially...To view the full article, register now.
Already a subscriber? Click here to view full article